Eric E. Poma - 25 Aug 2025 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)

Role
Chief Executive Officer, Director
Signature
/s/ Andrew Jackson, Attorney-in-fact
Issuer symbol
CLDI
Transactions as of
25 Aug 2025
Net transactions value
+$50,000
Form type
4
Filing time
25 Aug 2025, 20:47:39 UTC
Previous filing
25 Apr 2025
Next filing
05 Sep 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Eric E. Poma filed Form 4 for Calidi Biotherapeutics, Inc. (CLDI) on 25 Aug 2025."

Quick Takeaways

  • This page summarizes Eric E. Poma's Form 4 filing for Calidi Biotherapeutics, Inc. (CLDI).
  • 2 reported transactions and 1 derivative row are listed below.
  • Filing timestamp: 25 Aug 2025, 20:47.

What Changed

  • Previous filing in this sequence was filed on 25 Apr 2025.
  • Current net transaction value: +$50,000.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Poma Eric E Chief Executive Officer, Director C/O CALIDI BIOTHERAPEUTICS, INC., 4475 EXECUTIVE DRIVE, SUITE 200, SAN DIEGO, /s/ Andrew Jackson, Attorney-in-fact 25 Aug 2025 0001339484

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDI Common Stock Purchase $50,000 +25,000 $2.00* 25,000 21 Aug 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDI Warrant (right to buy) Purchase +25,000 25,000 21 Aug 2025 Common stock 25,000 $2.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The common stock and warrants were acquired by the reporting person in a public offering conducted by the Issuer that was closed on August 21, 2025.
F2 Each common share was purchased with an accompanying warrant for a purchase price of $2.00 per share and accompanying warrant.

Remarks:

Exhibit 24 - Power of Attorney

Sponsored